June 2026 Research Update

This month added more clarity that several newer complement-targeting medicines can control PNH-related red blood cell breakdown and improve anemia, with results that were mostly consistent across different study settings. Crovalimab (a C5 blocker) looked similar to eculizumab for key blood outcomes in a randomized trial subgroup, while iptacopan (an oral factor B blocker) and pegcetacoplan (a C3 blocker) were linked to higher hemoglobin and less need for transfusions in people switching from other treatments. Together, these studies reinforce that the main question is often which approach best fits a person's situation, rather than whether complement blocking works at all. [1] [2] [3] [4]

In complement inhibitor-naive Chinese adults, crovalimab and eculizumab had very similar rates of hemolysis control and hemoglobin stabilization over 24 weeks, and breakthrough hemolysis was uncommon in both groups. Crovalimab showed a greater improvement in fatigue scores, and most people on crovalimab reached complete blockage of the end of the complement pathway (terminal complement inhibition). Side effects were common in both groups, with somewhat fewer severe (grade 3-5) events reported with crovalimab in this subgroup analysis. [1]

For people who were already on stable anti-C5 treatment (eculizumab or ravulizumab) but still had room to improve, switching to oral iptacopan monotherapy was followed by a rise in hemoglobin of about 2.0 g/dL over 24 weeks. Markers linked to ongoing complement-related red cell problems on treatment (such as C3d on red blood cells) dropped close to zero, and people reported improved fatigue and treatment satisfaction. No breakthrough hemolysis or major vascular events were reported during the 24-week study period, while infections and other side effects were observed. [2]

Evidence for pegcetacoplan continued to point in the same direction across a meta-analysis and a real-world Spanish cohort: many patients achieved transfusion avoidance and higher hemoglobin after switching because prior therapy was not working well enough. In the meta-analysis of 271 patients, transfusion avoidance was reported in 80.6% and serious side effects in 16.6% (12% after one sensitivity analysis). In routine care in Spain, hemoglobin rose quickly and fewer patients needed transfusions, while mild side effects were reported and no thrombosis was observed during the reported follow-up. [3] [4]

One additional paper explored how crovalimab dosing might be individualized using computer simulations rather than patient outcome data. In these simulations, therapeutic drug monitoring-guided dosing reduced how much drug exposure varied between people and allowed longer time between doses for about 24% of patients, while keeping exposure similar to standard dosing. This is early modeling work, but it shows active research interest in making dosing schedules more flexible. [5]

For patients, this month mainly adds confidence that multiple complement-blocking options can achieve the core goals many people care about: controlling hemolysis, improving anemia, and sometimes improving fatigue. Some of the strongest evidence here comes from a randomized trial subgroup (crovalimab vs eculizumab) and from a controlled clinical trial without a comparison group (iptacopan switch study), while pegcetacoplan findings were supported by both pooled trial data and routine-care experience. What remains uncertain is how best to compare these options head-to-head across different patient groups and over longer time periods, especially for less common outcomes like major blood clots. The dosing simulation work is not something people would feel directly today, but it helps explain why future care might include more personalized schedules if confirmed in clinical studies. [1] [2] [3] [4] [5]

This month reinforced that blood clots remain a serious part of the PNH story, but the risk seen in studies depends strongly on the setting and what treatments are available. In an Indian cohort that did not include eculizumab treatment, thrombosis was reported in about 1 in 10 people with a PNH clone and was more common in those with larger clones and high disease activity. In Japan, clots still occurred in a subset of people treated with eculizumab, with signals that clots were more likely when hemolysis markers were higher and when antithrombotic medicines were not being used at the time. [6] [7]

In the Indian single-center study of 95 people with a PNH clone, thrombosis occurred in 10 patients (9.5%), most often in abdominal veins, and some patients had more than one clotting episode. All patients who developed thrombosis had a large granulocyte PNH clone and high disease activity, which supports the idea that more active PNH biology can coincide with higher clot risk. The report also described that fatal outcomes occurred in some of the patients who had thrombosis, underlining why clotting is closely watched in PNH research. [6]

In Japanese post-marketing surveillance of 794 people treated with eculizumab, 44 patients (5.5%) had at least one thrombotic event during follow-up. Events were more common in those with a history of thrombosis before starting eculizumab, and many events happened when LDH was at least 1.5 times the upper limit of normal, a lab signal of ongoing hemolysis. The report also noted that events were more often recorded during periods without antithrombotic therapy, and some occurred when dosing intervals were prolonged, which raises questions about whether some people had incomplete complement control at those times. [7]

A small pediatric cohort from Egypt illustrated how severe PNH can be in children and how outcomes may be shaped by delayed diagnosis and access to transplantation and newer drugs. Among 8 children (including classic PNH and aplastic anemia overlap), the report described high mortality, with several deaths occurring before transplant could be performed. In the 2 children who received ravulizumab, the authors reported rapid clinical and blood count improvement and transfusion independence, with only short-lived side effects. [8]

For patients and caregivers, these studies help clarify why research keeps focusing on clot risk: clots can still happen, and the studies point to higher disease activity, prior clot history, and possible incomplete control of hemolysis as situations where clots were seen more often. The evidence here comes from observational cohorts, so it cannot prove what caused individual clot events, but it does show real-world patterns that matter for future research and monitoring strategies. The pediatric report is a reminder that PNH can look different in children, and that outcomes may depend on system factors such as diagnostic delay and treatment availability. What remains uncertain is exactly which combination of lab markers, clone features, and treatment factors best predicts clot risk for an individual person across different countries and care settings. [6] [7] [8]

This month added two kinds of patient-level information that numbers alone do not capture: the day-to-day time costs of treatment, and rare clinical situations, such as PNH first showing up as blood clots inside the heart, or a PNH clone found alongside another blood disorder. The time-burden study makes clear that treatment days can take several hours and can affect work, travel, and scheduling. The case reports broaden the picture of how PNH clones can show up in complex immune settings or with uncommon clot locations, but they remain individual stories rather than general expectations. [9] [10] [11]

In a US mixed-methods study of adults on parenteral complement inhibitors (eculizumab, ravulizumab, or pegcetacoplan), people reported spending a median of 3 hours 15 minutes per treatment administration on treatment-related activities. Time demands varied by drug and delivery, and interviews described knock-on effects like missed work time, planning around infusion days, and needing help from family members. This study does not measure medical effectiveness, but it captures a real-life burden that can shape how people experience long-term therapy. [9]

One case report described a previously healthy 34-year-old woman whose first presentation of newly diagnosed PNH included progressive blood clots inside the heart chambers, found on heart imaging. After complement inhibition with eculizumab (later ravulizumab), follow-up imaging showed near-resolution of the clots and lab markers of hemolysis normalized. As a single case, it mainly serves as a reminder that PNH-related clotting can sometimes appear in unexpected locations and prompt rapid diagnostic workups. [10]

Two other case reports connected PNH-type cells with unusual immune blood disorders. One described a rare type of T-large granular lymphocytic leukemia occurring with severe aplastic anemia and a PNH clone, with discussion of T-cell driven bone marrow suppression as part of the explanation. Another described anti-CD19 CAR T-cell therapy for multi-refractory immune thrombocytopenia, where the patient had a durable platelet remission along with a transient expansion of PNH-type cells. [11] [12]

For patients, the time-burden study may matter now because it puts shared experiences into concrete terms, including travel, scheduling, and the need for support on treatment days. This kind of evidence does not say which treatment is best medically, but it does document impacts on daily life that are easy to overlook in clinical trials. The case reports are mainly for awareness and research context: they show that PNH clones can appear alongside other immune conditions, and that clotting can sometimes present in uncommon ways, but they cannot be used to predict what will happen for most people with PNH. What remains uncertain is how often these rare situations occur and which patient factors make them more likely, because single-patient reports cannot answer those frequency questions. [9] [10] [11] [12]